Wordt geladen...
Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
INTRODUCTION: Golimumab is a tumor necrosis factor-α (TNF-α) inhibitor for treatment of patients with severe, active ankylosing spondylitis. This study evaluated the cost-effectiveness of golimumab compared with conventional care and other TNF-α inhibitors in treatment of AS from the UK National Hea...
Bewaard in:
| Gepubliceerd in: | Rheumatol Ther |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Springer Healthcare
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5696295/ https://ncbi.nlm.nih.gov/pubmed/28956301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40744-017-0083-1 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|